700,000 Shares of Cumberland Pharmaceuticals Inc. $CPIX Purchased by Diversified Trust Co

Diversified Trust Co purchased a new position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 700,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $5,481,000. Diversified Trust Co owned approximately 4.67% of Cumberland Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Lantern Wealth Advisors LLC acquired a new stake in Cumberland Pharmaceuticals during the third quarter valued at approximately $106,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Cumberland Pharmaceuticals during the 1st quarter worth approximately $66,000. Bank of New York Mellon Corp bought a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter worth approximately $379,000. BlackRock Inc. bought a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter worth approximately $412,000. Finally, Dimensional Fund Advisors LP boosted its stake in Cumberland Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock valued at $898,000 after buying an additional 4,081 shares in the last quarter. Institutional investors own 15.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the company currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Down 11.3%

Shares of Cumberland Pharmaceuticals stock opened at $5.88 on Friday. Cumberland Pharmaceuticals Inc. has a 12-month low of $1.85 and a 12-month high of $9.28. The stock has a market capitalization of $88.08 million, a P/E ratio of 1.31 and a beta of 0.16. The company has a 50-day simple moving average of $6.64 and a 200 day simple moving average of $5.57.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions. Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation.